EPO and Parkinson disease: This dose of EPO is higher than the EPO dose, about 150 IU/kg, used to increase hematocrit in chronic renal disease (Thadhani et al., 2018), and a longer duration of treatment of PD subjects with EPO would be expected to cause a prohibitive increase in blood hematocrit leading to polycythemia.